Citations

Mayo Clinic

Clear

287 citation(s) found for "M, Singer".

Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study
Vernetti, Patricio Millar , Norcliffe‐Kaufmann, Lucy , Palma, Jose‐Alberto , Shibao, Cyndya A. , Goldstein, David S. , Low, Phillip A. , Miglis, Mitchell G. , Fanciulli, Alessandra , Millar Vernetti, Patricio , Goldstein, David S. , Singer, Wolfgang , Coon, Elizabeth Anne , Miglis, Mitchell G , Fanciulli, Alessandra , Kaufmann, Horacio , Palma, Jose-Alberto , Biaggioni, Italo , Shibao, Cyndya A , Peltier, Amanda , Freeman, Roy L. , Gibbons, Christopher H. , Coon, Elizabeth A. , Wenning, Gregor K. , Vernino, Steven , Betensky, Rebecca A.

Brain | February 13, 2024 | Volume: 147 | Issue: 7 | Pages: 2440-2448

10.1093/brain/awae033 | PMID 38366572 Get It

Abstract We aimed to describe the clinical features of patients with pure autonomic failure (PAF) preceding phenoconversion that could be useful as predictive markers for advancing α-synuclein-associated neurodegeneration of the brain. Patients diagnosed with PAF were evaluated at eight centres (seven US-based and one European) and enrolled in a longitudinal observational cohort study (NCT01799915). Subjects underwent detailed assessments of motor, sleep, olfactory, cognitive and autonomic function and were followed prospectively to determine whether they developed parkinsonism or dementia for up to 10 years. We identified incident cases of Parkinson's disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) and computed hazard ratios for phenoconversion as functions of clinical features. A total of 209 participants with PAF with a median disease duration of 6 years (IQR: 3–10) were enrolled. Of those, 149 provided follow-up information at an office or telemedicine visit. After a mean follow-up duration of 3 years, 48 (33%) participants phenoconverted (42% to PD, 35% to DLB and 23% to MSA). Faster phenoconversion from study enrolment to any diagnosis was associated with urinary and sexual dysfunction [hazard ratio (HR) 5.9, 95% confidence interval (CI): 1.6–22 and HR: 3.6, 95% CI: 1.1–12] followed by subtle motor signs (HR: 2.7, 95% CI: 1.2–6), trouble swallowing (HR 2.5, 95% CI: 1.4–4.5) and changes in speech (HR:2.4, 95% CI:1.1–4.8) at enrolment. Subjects reporting deterioration of handwriting were more likely to phenoconvert to PD (HR: 2.6, 95% CI: 1.1–5.9) and those reporting difficulty handling utensils were more likely to phenoconvert to DLB (HR: 6.8, 95% CI: 1.2–38). Patients with a younger age of PAF onset (HR: 11, 95% CI: 2.6–46), preserved olfaction (HR: 8.7, 95% CI: 1.7–45), anhidrosis (HR: 1.8, 95% CI: 1–3.1, P = 0.042) and severe urinary problems (HR 1.6, 95% CI: 1–2.5, P = 0.033) were more likely to phenoconvert to MSA. The best autonomic predictor of PD was a blunted heart rate increase during the tilt-table test (HR: 6.1, 95% CI: 1.4–26). Patients with PAF have an estimated 12% (95% CI: 9–15%) per year annual risk following study entry of phenoconverting to a manifest CNS synucleinopathy.
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
Bischoff, Lindsay , Fugazzola, Laura , Buczek, Erin , Haugen, Bryan R. , McIver, Bryan, McMullen, Caitlin , Newbold, Kate, Rocke, Daniel J. , Russell, Marika D. , Ryder, Mabel , Sherman, Eric J. , Shindo, Maisie L., Stack, Brendan C. , Wirth, Lori J. , Randolph, Gregory W. , Ryder, Mabel , Ganly, Ian , Faquin, William C , Sadow, Peter M. , Shonka, David C. , Singer, Michael C. , Wong, Richard J. , Randolph, Gregory William

JAMA Otolaryngology–Head & Neck Surgery | January 11, 2024 | Volume: 150 | Issue: 3 | Pages: 265

10.1001/jamaoto.2023.4323 | PMID 38206595 Get It

Importance Oncocytic (Hürthle cell) thyroid carcinoma is a follicular cell-derived neoplasm that accounts for approximately 5% of all thyroid cancers. Until recently, it was categorized as a follicular thyroid carcinoma, and its management was standardized with that of other differentiated thyroid carcinomas. In 2022, given an improved understanding of the unique molecular profile and clinical behavior of oncocytic thyroid carcinoma, the World Health Organization reclassified oncocytic thyroid carcinoma as distinct from follicular thyroid carcinoma. The International Thyroid Oncology Group and the American Head and Neck Society then collaborated to review the existing evidence on oncocytic thyroid carcinoma, from diagnosis through clinical management and follow-up surveillance. Observations Given that oncocytic thyroid carcinoma was previously classified as a subtype of follicular thyroid carcinoma, it was clinically studied in that context. However, due to its low prevalence and previous classification schema, there are few studies that have specifically evaluated oncocytic thyroid carcinoma. Recent data indicate that oncocytic thyroid carcinoma is a distinct class of malignant thyroid tumor with a group of distinct genetic alterations and clinicopathologic features. Oncocytic thyroid carcinoma displays higher rates of somatic gene variants and genomic chromosomal loss of heterozygosity than do other thyroid cancers, and it harbors unique mitochondrial DNA variations. Clinically, oncocytic thyroid carcinoma is more likely to have locoregional (lymph node) metastases than is follicular thyroid carcinoma—with which it was formerly classified—and it develops distant metastases more frequently than papillary thyroid carcinoma. In addition, oncocytic thyroid carcinoma rarely absorbs radioiodine. Conclusions and Relevance The findings of this review suggest that the distinct clinical presentation of oncocytic thyroid carcinoma, including its metastatic behavior and its reduced avidity to radioiodine therapy, warrants a tailored disease management approach. The reclassification of oncocytic thyroid carcinoma by the World Health Organization is an important milestone toward developing a specific and comprehensive clinical management for oncocytic thyroid carcinoma that considers its distinct characteristics.
Abstract 16187: COVID-19 and Outcomes of Acute Ischemic Stroke - A Nationwide Cross-Sectional Study
Singer, Emad , Tammineedi, Sai Niharika , Tar, Deen , KAPIL, LESLIE , Intsiful, Tarsha A, Duc, Huy Le, Mukesh, Sindu, Patel, Neelkumar , Abusharkh, Fathi, Singla, Ramit , Arumaithurai, Kogulavadanan , Mukesh, S. , Patel, Urvish , Diallo, Mamadou Saliou Kalifa , Ortíz, Juan Fernando , Patel, Smit D.

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16187 Get It

Introduction: Acute ischemic stroke (AIS) is thesecond leading cause of death globally, accounting for approximately 11% of alldeaths, long-term disability, and functional impairments in survivors. TheCOVID-19 pandemic has raised concerns about its impact on AIS patients. Aim: This study aimed to assess the outcomes,including mortality and severity of disability in AIS hospitalizations withCOVID-19. Methods: We performed a retrospective cross-sectionalanalysis of the Nationwide Inpatient Sample (NIS-2020) in adulthospitalizations for AIS to compare the outcomes [death & APRDRGseverity/disability] in COVID-19 patients using ICD-10 codes. We performedweighted analyses using chi-square, unpaired t-test, and multivariate logisticregression models to evaluate COVID-19-associated poor outcomes amongst AISpatients. Results: Out of 504,460 AIS patients, 7,590 had AIStriggered by COVID-19. Amongst AIS hospitalizations, COVID-19 was more frequentin age group >65 year old 63.2%, male 52.6%, White race (51.4%), patientwith Medicare (58.7%), median household income 0-25 percentile (33.6%), Southzone (43.4%), and hypertensives (83.7%). AIS patients with COVID-19 had ahigher mortality (10.93% vs 3.8%) and severe/extreme disability (93.21% vs37.43%) rates in comparison to patients without COVID-19. (p<0.0001) Inregression analysis COVID-19 was associated with 213% higher odds of mortality(aOR: 3.13, 95% CI: 2.90-3.38, p<0.0001, c:0.671) and higher odds of severe/extreme disability(26.85, 24.53-29.39, p<0.0001, c:0.686) compared to AIS patients withoutCOVID-19. Conclusion: These findings emphasize the substantialimpact of COVID-19 on AIS patients by elevating mortality and risk of severedisability compared to their counterparts. Efforts should be directed towards earlyidentification of stroke population that is at higher risk ofCOVID-19-associated poor outcome and prompt management tomitigate the burden of the both diseases.
WATS3D: An Interobserver Study of Barrett's Esophagus–Associated Dysplasia Among Gastrointestinal Pathologists
Patil, Deepa T. , Goldblum, John R. , Lauwers, Gregory Y. , Lewis, Jason T., Robert, Marie E. , Odze, Robert D. , Lewis, Jason T., Singer, Mendel E.

Clinical and Translational Gastroenterology | December 13, 2023 | Volume: 15 | Issue: 2 | Pages: e00661

10.14309/ctg.0000000000000661 | PMID 38088399 Get It

INTRODUCTION: Wide-area transepithelial sampling with 3-dimensional computer-assisted analysis (WATS 3D ) has been shown to increase the detection rate of dysplasia (and intestinal metaplasia) in patients with Barrett's esophagus (BE). The purpose of this study was to evaluate the interobserver variability and accuracy of diagnosing BE-associated dysplasia in WATS 3D specimens among gastrointestinal (GI) pathologists without prior experience with this technology. METHODS: Five GI pathologists underwent a 4-hour in-person (at microscope) and virtual training session and then evaluated digital images of discrete cellular foci from 60 WATS 3D cases with BE (20 nondysplastic BE [NDBE], 20 low-grade dysplasia [LGD], and 20 high-grade dysplasia/esophageal adenocarcinoma [HGD/EAC]). Each case consisted of 1 hematoxylin and eosin–stained image (cell block), and 1 liquid cytology or papanicolaou-stained smear image (120 images in total). RESULTS: The overall kappa value among the 5 study pathologists was excellent (overall kappa = 0.93; kappa = 0.93 and 0.97 for cell block and smear specimens, respectively). There were no significant differences noted in kappa values in interpretation of the cell block vs smear specimens or in any of the individual diagnostic categories when the latter were evaluated separately. Furthermore, agreement was perfect (100%) regarding detection of neoplasia (either LGD, HGD, or EAC). Diagnoses were made with complete confidence in 91% of instances. DISCUSSION: We conclude that GI pathologists, without any prior experience in interpretation of WATS 3D specimens, can undergo a short training session and then diagnose these specimens with a very high level of accuracy and reproducibility.
Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy Results in Growth Factor Spike (S12.002)
Schmeichel, Ann M., Minota, Karla, Zeller, Anita, Schmelzer, James D., Gehrking, Tonette L., Sletten, David M., Gehrking, Jade A., Low, Phillip A. , Singer, Wolfgang , Dietz, Allan B.

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s12.002 Get It

Multiple System Atrophy Presenting as Motor Neuron Disease (P6.069)
Jones, Lauren Thornton, Nelson, Renée, Bower, James H., Matsumoto, Joseph Y., Sandroni, Paola , Benarroch, Eduardo E. , Suarez, Mariana, Low, Phillip A. , Nelson, Renee, Singer, Wolfgang , Coon, Elizabeth A.

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p6.069 Get It

Diagnostic Yield of REM Sleep Muscle Activity for Presumed Synucleinopathy Neurodegeneration (N7.001)
Feemster, John, Tabatabai, Grace, Sandness, David J., Timm, Paul, McCarter, Allison R., Talley, Heather N., Johnson, Katie L. , Savica, Rodolfo , Josephs, Keith A. , Boeve, Bradley, Silber, Michael H. , McCarter, Stuart J. , Vemuri, Prashanthi , Mielke, Michelle M. , Machulda, Mary M. , Kantarci, Kejal , Singer, Wolfgang , Coon, Elizabeth A. , Louis, Erik K. St.

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.n7.001 Get It

Peripheral Nerve Amyloidosis: Phenotype, Natural History, And Autonomic Dysfunction In Inherited Versus Acquired Subtypes (S36.008)
Loavenbruck, Adam , Sandroni, Paola , Dyck, P. James B. , Low, Phillip, Singer, Wolfgang , Mauermann, Michelle L. , Klein, Christopher J.

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s36.008 Get It

Comparison of Baroreflex Sensitivity to Fall and Rise in Blood Pressure Induced by the Valsalva Maneuver (S36.007)
Wada, Naoki , Gehrking, Tonette L., Sletten, David M., Schmelzer, James D., Low, Phillip A. , Wada, Naoki, Singer, Wolfgang

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s36.007 Get It

Randomized Trial of Rifampicin in MSA: Effect on Autonomic Function (S16.006)
Fealey, Robert D., Sandroni, Paola , Ahlskog, J. Eric , Matsumoto, Joseph Y., Bower, James H., Burnett, Melinda S. , Gehrking, Tonette L., Gehrking, Jade A., Benarroch, Eduardo E. , Low, Phillip A. , Singer, Wolfgang , Cheshire, William P. , McKeon, Andrew

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s16.006 Get It